Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

Statements of Loss

(in CHF thousands except for share and per share data)

 

For the Years Ended

December 31, 

  Note   2018   2017   2016
Revenues              
Contract revenue 11   7,194   20,255   23,214
Total revenue     7,194   20,255   23,214
               
Operating expenses              
Research & development expenses 12   (44,277)   (32,663)   (25,774)
General & administrative expenses 12   (12,467)   (10,131)   (7,896)
               
Total operating expenses     (56,744)   (42,794)   (33,670)
               
Operating loss     (49,550)   (22,539)   (10,456)
Finance income / (expense), net 12   (1,132)   (4,055)   3,324
Interest income 12   29   330   43
Interest expense 12   (298)   (147)   (7)
Finance result, net     (1,401)   (3,872)   3,360
Loss before tax     (50,951)   (26,411)   (7,096)
Income tax expense 14      
Loss for the period     (50,951)   (26,411)   (7,096)
Loss per share (EPS):              
Basic and diluted, loss for the period attributable to equity holders 18   (0.82)   (0.46)   (0.14)
                 

Statements of Comprehensive Loss

(in CHF thousands)

     

For the Years Ended

December 31,

      2018   2017   2016
               
Loss for the period     (50,951)   (26,411)   (7,096)
Other comprehensive loss not to be reclassified to income or loss in subsequent periods (net of tax)              
Re-measurement losses on defined benefit plans (net of tax of CHF 0 for all periods) 15   (302)   (780)   (761)
Total comprehensive loss, net of tax     (51,253)   (27,191)   (7,857)

 

The accompanying notes are an integral part of these financial statements.

 

 F-5


© AC Immune 2015